WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100414
Description: Glyciphosphoramide is a DNA crosslinking agent with anticancer activity. Glyciphosphoramide (GPA) belongs to the group of phosphoramide mustard anticancer agents. It has apparent antitumor effects in some animal models and in clinical trials against breast cancer, lymphosarcoma, uterocervical cancer and cancerous ulcer with good results.
MedKoo Cat#: 100414
Chemical Formula: C12H24Cl2N3O4P
Exact Mass: 375.08815
Molecular Weight: 376.21
Elemental Analysis: C, 38.31; H, 6.43; Cl, 18.85; N, 11.17; O, 17.01; P, 8.23
Glyciphosphoramide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: BRN 2012594; M 25; LS72312; Z6202; M 256202; M256202.
IUPAC/Chemical Name: 2-[[bis(2-chloroethyl)amino-[(2-ethoxy-2-oxoethyl)amino]phosphanyl] amino]acetate
InChi Key: IOBSTYBMPYRWQR-UHFFFAOYSA-M
InChi Code: InChI=1S/C10H20Cl2N3O4P/c1-2-19-10(18)8-14-20(13-7-9(16)17)15(5-3-11)6-4-12/h13-14H,2-8H2,1H3,(H,16,17)/p-1
SMILES Code: O=C([O-])CNP(N(CCCl)CCCl)NCC(OCC)=O
The following data is based on the product molecular weight 376.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wang WJ, Bai JY, Zhu XY. [Determination of glyciphosphoramide and its metabolite in plasma and the pharmacokinetics in rats after oral administration]. Yao Xue Xue Bao. 1993;28(10):738-43. Chinese. PubMed PMID: 8009985.
2: He S, Ji XJ, Zhu TX, Wang NG, Su XL, Cao FZ, Pan ZK, Li ZR, Bao TT, Han R. [A study of the antitumor action of glyciphosphoramide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Oct;6(5):334-7. Chinese. PubMed PMID: 6241082.
3: Sun Y. [Clinical phase II trial of a new antineoplastic drug, glyciphosphoramide (GPM)]. Zhonghua Zhong Liu Za Zhi. 1984 Sep;6(5):375-8. Chinese. PubMed PMID: 6534723.
4: Wang ZY. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs]. Zhonghua Zhong Liu Za Zhi. 1984 Sep;6(5):379-81. Chinese. PubMed PMID: 6398774.
5: Guo JY, Huang L, Tian SH, Zhao QR. [Synthesis of the 14C labelled anticancer agent: N,N-bis(beta-chloroethyl)-N',N"-di(carboethoxy-[14C] methyl)-phosphorotriamide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Aug;6(4):295-7. Chinese. PubMed PMID: 6241072.
6: Sun Y. [Clinical phase II trial of a new antineoplastic drug--glyciphosphoramide]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Aug;6(4):273-6. Chinese. PubMed PMID: 6241067.
7: Sun Y. [Clinical phase I trial of a new anti-neoplastic drug--glyciphosphoramide]. Zhonghua Zhong Liu Za Zhi. 1984 Jul;6(4):293-5. Chinese. PubMed PMID: 6525950.
The antitumor activity of oral glyciphosphoramide was demonstrated in tumor-bearing animals (mice, rats, and dogs). In mice, the LD50 for oral and i.p. I were 580 and 360 mg/kg, resp. The max. tolerated dose of I in dogs was 20 mg/kg/day. In normal rats, 14C-radioactivity in blood reached its peak 8 h after oral administration of I-14C. The tissue distribution of I-14C in normal and tumor-bearing rats was similar, the radioactivity being highest in liver, kidney, and gastrointestinal tract and tumor tissue. The cumulative excretion of 14C-radioactivity in urine and feces was 32.54% within 96 h. see: Zhongguo Yixue Kexueyuan Xuebao (1984), 6(5), 334-7.